Download PDF
Arthritis und Rheuma 2013; 33(06): 347-361
DOI: 10.1055/s-0037-1618204
Alltägliches in der kinderrheumatologischen Praxis?
Schattauer GmbH

Vaskulitiden im Kindesalter

Childhood vasculitis
J. Thomas
1   Pädiatrische Rheumatologie, Klinik für Kinder- und Jugendmedizin, Universitätsklinikum Tübingen
,
J. B. Kümmerle-Deschner
1   Pädiatrische Rheumatologie, Klinik für Kinder- und Jugendmedizin, Universitätsklinikum Tübingen
› Author Affiliations
Further Information

Publication History

Publication Date:
27 December 2017 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die primären Vaskulitiden sind sehr seltene Erkrankungen im Kindesalter. Die häufigsten Formen sind die Purpura Schönlein-Henoch und das Kawasaki-Sydrom, die einen selbstlimitierenden Verlauf zeigen. Die Ätiopathogenese der Vaskulitiden ist meist noch unklar. Umweltfaktoren wie Infektionen scheinen bei prädisponierten Personen eine verstärkte inflammatorische Antwort auszulösen. Die Klassifikationskriterien der Vaskulitiden im Erwachsenenalter wurden 2008 durch die der europäischen Fachgesellschaft für Kinderrheumatologie (PRES) mit den Vaskulitiden im Kindesalter ergänzt. Die meisten Therapieempfehlungen leiten sich jedoch aus Studienergebnissen aus dem Erwachsenenalter ab. Diese Übersichtsarbeit fasst die aktuellen Klassifikationskriterien, Pathogenesen, klinischen Manifestationen und Therapieprotokolle bei Vaskulitiden im Kindesalter zusammen.

Summary

The primary vasculitides are rare conditions in childhood. The most frequent disease manifestations are Purpura Schoenlein-Henoch and Kawasaki’s syndrome, which usually have a self-limiting course. In the majority of vasculitides, the etiology remains unknown. Environmental factors as well as infections are suspected to trigger an auto-inflammatory response in predisposed individuals. The vasculitides in childhood have been amended to the classification criteria of the vasculitides in adulthood in 2008. Most therapy guidelines for children are adapted from results of studies in adults. This review covers the currrent classifications, pathogenesis, clinical manifestations and therapy recommendations for children.

Schlüsselwörter

Primäre Vaskulitiden - Purpura Schönlein-Henoch - Kawasaki-Sydrom - Klassifikationskriterien

Keywords

Primary vaskulitides - Purpura Schoenlein-Henoch - Kawasaki’s syndrome - classifications
 

  • Literatur

  • 1 Dedeoglu F, Sundel RP. Vasculitis in children. Pediatric clinics of North America 2005; 52 (02) 547-575.
    CrossrefPubMedSearch in Google Scholar
  • 2 Ozen S, Pistorio A, Iusan SM. et al. EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis, Ankara 2008, Part II: Final classification criteria. Annals of the rheumatic diseases 2010; 69 (05) 798-806.
    CrossrefPubMedSearch in Google Scholar
  • 3 Ozen S, Ruperto N, Dillon MJ. et al. EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis 2006; 65 (07) 936-941.
    CrossrefPubMedSearch in Google Scholar
  • 4 Gardner-Medwin JM, Dolezalova P, Cummins C, Southwood TR. Incidence of Henoch-Schonlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet 2002; 360 (9341) 1197-1202.
    CrossrefPubMedSearch in Google Scholar
  • 5 Mohan N, Edwards ET, Cupps TR. et al. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. The Journal of rheumatology 2004; 31 (10) 1955-1958.
    PubMedSearch in Google Scholar
  • 6 Reinehr T, Burk G, Andler W. Does steroid treatment of abdominal pain prevent renal involvement in Henoch-Schonlein purpura?. Journal of pediatric gastroenterology and nutrition 2000; 31 (03) 323-324.
    CrossrefPubMedSearch in Google Scholar
  • 7 Ronkainen J, Koskimies O, Ala-Houhala M. et al. Early prednisone therapy in Henoch-Schonlein purpura: a randomized, double-blind, placebo-controlled trial. The Journal of pediatrics 2006; 149 (02) 241-247.
    CrossrefPubMedSearch in Google Scholar
  • 8 Hospach T, Huppertz HI. [Henoch-Schonlein purpura : most frequent form of vasculitis in childhood and adolescence]. Zeitschrift fur Rheumatologie 2011; 70 (10) 829-837.
    CrossrefPubMedSearch in Google Scholar
  • 9 Narchi H. Risk of long term renal impairment and duration of follow up recommended for Henoch-Schonlein purpura with normal or minimal urinary findings: a systematic review. Archives of disease in childhood 2005; 90 (09) 916-920.
    CrossrefPubMedSearch in Google Scholar
  • 10 Goldstein AR, White RH, Akuse R, Chantler C. Long-term follow-up of childhood Henoch-Schonlein nephritis. Lancet 1992; 339 (8788) 280-282.
    CrossrefPubMedSearch in Google Scholar
  • 11 Ronkainen J, Nuutinen M, Koskimies O. The adult kidney 24 years after childhood Henoch-Schonlein purpura: a retrospective cohort study. Lancet 2002; 360 (9334) 666-670.
    CrossrefPubMedSearch in Google Scholar
  • 12 Wagner N, Dannecker G. Pädiatrische Rheumatologie. Berlin, Heidelberg, New York: Springer; 2013
    Search in Google Scholar
  • 13 Saulsbury FT. Henoch-Schonlein purpura in children. Report of 100 patients and review of the literature. Medicine 1999; 78 (06) 395-409.
    CrossrefPubMedSearch in Google Scholar
  • 14 Newburger JW, Fulton DR. Kawasaki disease. Current opinion in pediatrics 2004; 16 (05) 508-514.
    CrossrefPubMedSearch in Google Scholar
  • 15 Cimaz R, Sundel R. Atypical and incomplete Kawasaki disease. Best practice & research 2009; 23 (05) 689-697.
    Search in Google Scholar
  • 16 Kobayashi T, Saji T, Otani T. et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet 2012; 379 (9826) 1613-1620.
    CrossrefPubMedSearch in Google Scholar
  • 17 Shirley DA, Stephens I. Primary treatment of incomplete Kawasaki disease with infliximab and methylprednisolone in a patient with a contraindication to intravenous immune globulin. The Pediatric infectious disease journal 2010; 29 (10) 978-979.
    CrossrefPubMedSearch in Google Scholar
  • 18 Newburger JW, Takahashi M, Gerber MA. et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 2004; 114 (06) 1708-1733.
    CrossrefPubMedSearch in Google Scholar
  • 19 Batu ED, Ozen S. Pediatric vasculitis. Current rheumatology reports 2012; 14 (02) 121-129.
    CrossrefPubMedSearch in Google Scholar
  • 20 Ozen S. The „other“ vasculitis syndromes and kidney involvement. Pediatric nephrology (Berlin, Germany) 2009; 25 (09) 1633-1639.
    PubMedSearch in Google Scholar
  • 21 Twilt M, Benseler S, Cabral D. Granulomatosis with polyangiitis in childhood. Current rheumatology reports 2012; 14 (02) 107-115.
    CrossrefPubMedSearch in Google Scholar
  • 22 Hernandez-Rodriguez J, Hoffman GS. Updating single-organ vasculitis. Current opinion in rheumatology 2011; 24 (01) 38-45.
    Search in Google Scholar
  • 23 Rodriguez-Pla A, Stone JH. Vasculitis and systemic infections. Current opinion in rheumatology 2006; 18 (01) 39-47.
    CrossrefPubMedSearch in Google Scholar
  • 24 Mukhtyar C, Guillevin L, Cid MC. et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Annals of the rheumatic diseases 2009; 68 (03) 310-317.
    CrossrefPubMedSearch in Google Scholar
  • 25 Fathalla BM, Miller L, Brady S, Schaller JG. Cutaneous polyarteritis nodosa in children. Journal of the American Academy of Dermatology 2005; 53 (04) 724-728.
    CrossrefPubMedSearch in Google Scholar
  • 26 Ozen S, Anton J, Arisoy N. et al. Juvenile polyarteritis: results of a multicenter survey of 110 children. The Journal of pediatrics 2004; 145 (04) 517-522.
    CrossrefPubMedSearch in Google Scholar
  • 27 Hoffman GS, Thomas-Golbanov CK, Chan J. et al. Treatment of subglottic stenosis, due to Wegener’s granulomatosis, with intralesional corticosteroids and dilation. The Journal of rheumatology 2003; 30 (05) 1017-1021.
    PubMedSearch in Google Scholar
  • 28 Savage CO, Harper L, Adu D. Primary systemic vasculitis. Lancet 1997; 349 (9051) 553-558.
    CrossrefPubMedSearch in Google Scholar
  • 29 Vanoni F, Bettinelli A, Keller F. et al. Vasculitides associated with IgG antineutrophil cytoplasmic autoantibodies in childhood. Pediatric nephrology (Berlin, Germany) 2009; 25 (02) 205-212.
    PubMedSearch in Google Scholar
  • 30 Zwerina J, Eger G, Englbrecht M. et al. Churg-Strauss syndrome in childhood: a systematic literature review and clinical comparison with adult patients. Seminars in arthritis and rheumatism 2009; 39 (02) 108-115.
    CrossrefPubMedSearch in Google Scholar
  • 31 Noth I, Strek ME, Leff AR. Churg-Strauss syndrome. Lancet 2003; 361 (9357) 587-594.
    CrossrefPubMedSearch in Google Scholar
  • 32 Masi AT, Hunder GG, Lie JT. et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis and rheumatism 1990; 33 (08) 1094-1100.
    PubMedSearch in Google Scholar
  • 33 Moosig F, Gross WL, Herrmann K. et al. Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome. Annals of internal medicine 2011; 155 (05) 341-343.
    CrossrefPubMedSearch in Google Scholar
  • 34 Brunner J, Feldman BM, Tyrrell PN. et al. Takayasu arteritis in children and adolescents. Rheumatology (Oxford, England) 2010; 49 (10) 1806-1814.
    CrossrefPubMedSearch in Google Scholar
  • 35 Watts R, Al-Taiar A, Mooney J. et al. The epidemiology of Takayasu arteritis in the UK. Rheumatology (Oxford, England) 2009; 48 (08) 1008-1011.
    CrossrefPubMedSearch in Google Scholar
  • 36 Berman DP, Lewis AB, Kung GC. Case Report of a 2-year-old boy with Takayasu’s arteritis: an atypical, severe presentation of a rare disease. Pediatric cardiology 2010; 31 (07) 1089-1092.
    CrossrefPubMedSearch in Google Scholar
  • 37 Magge SN, Chen HI, Stiefel MF. et al. Multiple ruptured cerebral aneurysms in a child with Takayasu arteritis. Journal of neurosurgery 2008; 1 (01) 83-87.
    Search in Google Scholar
  • 38 Uppal SS, Verma S. Analysis of the clinical profile, autoimmune phenomena and T cell subsets (CD4 and CD8) in Takayasu’s arteritis: a hospital-based study. Clinical and experimental rheumatology 2003; 21 (06) (Suppl. 32) S112-S116.
    PubMedSearch in Google Scholar
  • 39 Takahashi K, Oharaseki T, Yokouchi Y. et al. A half-century of autopsy results – incidence of pediatric vasculitis syndromes, especially Kawasaki disease. Circ J 2012; 76 (04) 964-970.
    CrossrefPubMedSearch in Google Scholar
  • 40 Sharma BK, Jain S, Radotra BD. An autopsy study of Takayasu arteritis in India. International journal of cardiology 1998; 66 (Suppl. 01) S85-S90 discussion S1.
    CrossrefPubMedSearch in Google Scholar
  • 41 Kerr GS, Hallahan CW, Giordano J. et al. Takayasu arteritis. Annals of internal medicine 1994; 120 (11) 919-929.
    CrossrefPubMedSearch in Google Scholar
  • 42 Mukhtyar C, Guillevin L, Cid MC. et al. EULAR recommendations for the management of large vessel vasculitis. Annals of the rheumatic diseases 2009; 68 (03) 318-323.
    CrossrefPubMedSearch in Google Scholar
  • 43 Mekinian A, Neel A, Sibilia J. et al. Efficacy and tolerance of infliximab in refractory Takayasu arteritis: French multicentre study. Rheumatology (Oxford, England) 2012; 51 (05) 882-886.
    CrossrefPubMedSearch in Google Scholar
  • 44 Abisror N, Mekinian A, Lavigne C. et al. Tocilizumab in refractory Takayasu arteritis: A case series and updated literature review. Autoimmunity reviews. 2013 Jun 29.
    PubMedSearch in Google Scholar
  • 45 Salvarani C, Magnani L, Catanoso M. et al. Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology (Oxford, England) 2012; 51 (01) 151-156.
    CrossrefPubMedSearch in Google Scholar
  • 46 Hoyer BF, Mumtaz IM, Loddenkemper K. et al. Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab. Annals of the rheumatic diseases 2011; 71 (01) 75-79.
    PubMedSearch in Google Scholar
  • 47 Liang P, Hoffman GS. Advances in the medical and surgical treatment of Takayasu arteritis. Current opinion in rheumatology 2005; 17 (01) 16-24.
    CrossrefPubMedSearch in Google Scholar
  • 48 Karincaoglu Y, Borlu M, Toker SC. et al. Demographic and clinical properties of juvenile-onset Behcet’s disease: A controlled multicenter study. Journal of the American Academy of Dermatology 2008; 58 (04) 579-584.
    CrossrefPubMedSearch in Google Scholar
  • 49 Kone-Paut I, Gorchakoff-Molinas A, Weschler B, Touitou I. Paediatric Behcet’s disease in France. Annals of the rheumatic diseases 2002; 61 (07) 655-656.
    CrossrefPubMedSearch in Google Scholar
  • 50 Kone-Paut I, Yurdakul S, Bahabri SA. et al. Clinical features of Behcet’s disease in children: an international collaborative study of 86 cases. The Journal of pediatrics 1998; 132 (04) 721-725.
    CrossrefPubMedSearch in Google Scholar